Soft Tissue Sarcoma | Primary Research (KOL's Insight) | Market Intelligence | Epidemiology & Market Forecast-2035

The tissues that connect, support, and encircle other body structures can develop soft tissue sarcoma, a rare form of cancer. This includes the tendons, joint linings, blood vessels, nerves, muscles, and fat. Soft tissue sarcomas come in more than 50 different subtypes. Some types tend to affect kids more than others, with adults being the primary target of others. In comparison to adults, children are more likely to develop soft tissue sarcomas. Instead of affecting a small area, it spreads throughout the body and appears as a tiny, growing bump that is painless. Different tumors can either be benign or malignant. Malignant soft tissue tumors spread throughout the body by metastasizing, which is the uncontrolled growth of the tumor into nearby tissues. Soft tissue sarcomas are typically treated with surgery. Surgery typically entails the removal of both the cancer and some nearby healthy tissue. Chemotherapy to shrink the tumor may be considered if soft tissue sarcomas affect the arms and legs in order to avoid amputation.

Description

The tissues that connect, support, and encircle other body structures can develop soft tissue sarcoma, a rare form of cancer. This includes the tendons, joint linings, muscles, fat, blood vessels, and nerves. Soft tissue sarcomas come in more than 50 different subtypes. Some types tend to affect kids more than others, with adults being the primary target of others. Because they can be mistaken for numerous other tumor types, these tumors can be challenging to diagnose. Although soft tissue sarcomas can develop anywhere on the body, the arms, legs, and abdomen are where they most frequently do. The most frequent form of treatment is surgical resection, but radiation and chemotherapy may also be suggested depending on the tumor's size, type, location, and severity. Sarcomas can develop anywhere in the body's soft tissues in adults. The majority of them, though, are in the hands and feet. Adults are more likely to develop metastases from soft tissue tumors, in part because these tumors are more likely to develop in the arms and legs and to spread to the lymph nodes. Soft tissue sarcomas that can spread to the lymph nodes include synovial sarcoma, rhabdomyosarcoma, and epithelial sarcoma, for instance. With more than 50% of all soft tissue sarcomas in children being rhabdomyosarcoma, it is the most prevalent type in this age group. Muscles can develop rhabdomyosarcoma, which is more common in the head and neck region. Men are slightly more likely than women to develop rhabdomyosarcoma. A high rate of morbidity is also present in children who are exposed to chemicals and chemical pollution. Additionally, if the child's father smoked, the likelihood of developing rhabdomyosarcoma increased.

Soft Tissue Sarcoma (Epidemiology)

Children experience soft tissue sarcomas more frequently than adults do. It spreads throughout the body rather than affecting a single small area and appears as a tiny, growing bump that is painless. Different tumors can either be benign or malignant. Malignant soft tissue tumors spread throughout the body by metastasizing, which is the uncontrolled growth of the tumor into nearby tissues. It primarily affects the lower lymphatic system and can manifest with a variety of symptoms at any age. The surrounding organs become congested as adenomas grow in place rather than spreading to other areas of the body. Early detection of soft tissue sarcomas can help with treatment. Patients with sarcomas have a 5-year survival rate of up to 90%, but unfortunately, this rate is very low. Unluckily, within the first two years of treatment, 70% of patients experience a recurrence of soft tissue sarcoma. Approximately 1 to 5 cases per 100,000 people per year are reported to occur internationally. 30.5% of 100,000 men and women experience a new case of soft tissue cancer each year. Per 100,000 men and women, there are 1.3 fatalities each year. These figures are age-adjusted and based on incidents from 2014 to 2018 and fatalities from 2015 to 2019. Approximately 84% of sarcoma diagnoses in Europe are soft tissue sarcomas. Due to their rarity and morphological heterogeneity, it is difficult to precisely identify these units. Nevertheless, particular histological patterns are frequently linked to the site of origin. For instance, young adults with liposarcoma tend to develop the disease in their thighs, while older patients with myxoid fibrosarcoma tend to develop the disease in their superficial soft tissues. In Europe, liposarcoma (16%), unspecified sarcoma (NOS, 14%), and leiomyosarcoma (19%) were the most prevalent types of soft tissue sarcoma.

Soft Tissue Sarcoma -Current Market Size & Forecast Trends

The market for soft tissue sarcoma is expected to grow significantly, with estimates indicating a value of approximately USD 315 million in 2024, projected to reach around USD 420 million by 2031, reflecting a compound annual growth rate (CAGR) of 4.2% during this period. This growth is driven by increasing investments in research and development for better treatment options, rising awareness of soft tissue sarcoma, and advancements in healthcare infrastructure. Major pharmaceutical players are focusing on developing new drugs and combination therapies, which will further enhance market dynamics. Overall, the soft tissue sarcoma market is well-positioned for substantial growth through 2035 as new therapies and treatment strategies continue to emerge.

Surgery is frequently used to treat soft tissue sarcomas. Surgery typically entails the removal of both the cancer and some healthy tissue surrounding it. Chemotherapy may be considered to shrink the tumor if soft tissue sarcomas affect the arms and legs in order to avoid amputation. Surgery is the primary therapy for stage I sarcoma. It was deemed acceptable if the margin was greater than 1 cm or the fascia was still whole. Re-resection or adjuvant external beam radiation therapy (XRT) is advised to prevent local recurrence if the margin is less than 1 cm, or the site is challenging to resect at the time of the recurrence. The National Comprehensive Cancer Network (NCCN) steering groups generally favor preoperative RT, especially in patients receiving high-volume therapy. Surgery followed by RT or surgery after RT is the only option for patients with resectable stage II disease. Preoperative or postoperative radiation therapy with consideration of adjuvant chemotherapy are options for patients with resectable stage III cancer (NCCN guideline panels typically favor preoperative radiation therapy, especially in large patient populations). Other options include radiation therapy after surgery alone or in combination with adjuvant chemotherapy, surgery after chemotherapy when adjuvant chemotherapy is taken into consideration, and surgery after chemotherapy. The difference between localized and metastatic metastases in diseases with metastatic spread must be made. To increase overall survival (OS) and disease-free survival (DFS), localized metastases affecting just one organ ought to be given thought. Only palliative care (radiotherapy, chemotherapy), surgery, or supportive care can be used to treat diffuse metastases. The histology, tumor growth rate, chemosensitivity, and associated symptoms should all be taken into account before palliative chemotherapy is started. as a top-notch treatment. In the treatment of metastatic disease, both single-agent and combination chemotherapy regimens are frequently used. While many combination therapies have higher response rates than single-agent chemotherapy, they are also more toxic and do not improve survival.

Report Highlights

Soft Tissue Sarcoma - Current Market Trends

Soft Tissue Sarcoma - Current & Forecasted Cases across the G8 Countries

Soft Tissue Sarcoma - Market Opportunities and Sales Potential for Agents

Soft Tissue Sarcoma - Patient-based Market Forecast to 2035

Soft Tissue Sarcoma - Untapped Business Opportunities

Soft Tissue Sarcoma - Product Positioning Vis-a-vis Competitors' Products

Soft Tissue Sarcoma - KOLs Insight